

## ZNHIT3 Polyclonal Antibody

**catalog number: E-AB-19558**

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Reactivity</b>	Human
<b>Immunogen</b>	Synthetic peptide of human ZNHIT3
<b>Host</b>	Rabbit
<b>Isotype</b>	IgG
<b>Purification</b>	Antigen affinity purification
<b>Buffer</b>	Phosphate buffered solution, pH 7.4, containing 0.05% stabilizer and 50% glycerol.


### Applications

Applications	Recommended Dilution
IHC	1:40-1:250

### Data



Immunohistochemistry of paraffin-embedded Human lung cancer tissue using ZNHIT3 Polyclonal Antibody at dilution of 1:80 (x200)



Immunohistochemistry of paraffin-embedded Human liver cancer tissue using ZNHIT3 Polyclonal Antibody at dilution of 1:80 (x200)

### Preparation & Storage

<b>Storage</b>	Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.
<b>Shipping</b>	The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.

### Background

ZNHIT3 (zinc finger, HIT-type containing 3), also known as TRIP3 (thyroid receptor-interacting protein 3) or HNF-4a coactivator, is a 155 amino acid protein that contains one HIT-type zinc finger and regulates PPAR-mediated adipocyte differentiation. ZNHIT3 also coactivates HNF-4, and as a thyroid receptor interacting protein, ZNHIT3 interacts with the ligand binding domain of the thyroid receptor. The gene encoding ZNHIT3 maps to human chromosome 17, which comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes.

### For Research Use Only